EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionSanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) Share XEHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionhttps://pharmaphorum.com/news/eha21-sanofi-builds-case-for-rare-disease-drug-sutimlimab-after-fda-rejection/
